-
Tytuł:
-
Association of Body Fat Percentage with Time in Range Generated by Continuous Glucose Monitoring during Continuous Subcutaneous Insulin Infusion Therapy in Type 2 Diabetes.
-
Autorzy:
-
Ruan Y; Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282 Guangdong, China.
Zhong J; Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282 Guangdong, China.
Chen R; Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282 Guangdong, China.
Zhang Z; Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282 Guangdong, China.
Liu D; Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282 Guangdong, China.
Sun J; Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282 Guangdong, China.
Chen H; Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282 Guangdong, China.
-
Źródło:
-
Journal of diabetes research [J Diabetes Res] 2021 May 28; Vol. 2021, pp. 5551216. Date of Electronic Publication: 2021 May 28 (Print Publication: 2021).
-
Typ publikacji:
-
Journal Article; Observational Study
-
Język:
-
English
-
Imprint Name(s):
-
Publication: <2019>-: London, United Kingdom : Hindawi Limited
Original Publication: Nasr City, Cairo : Hindawi Publishing Corporation, [2013]-
-
MeSH Terms:
-
Adiposity*
Blood Glucose Self-Monitoring*
Glycemic Control*/adverse effects
Insulin Infusion Systems*/adverse effects
Blood Glucose/*drug effects
Diabetes Mellitus, Type 2/*drug therapy
Hypoglycemic Agents/*administration & dosage
Insulin/*administration & dosage
Obesity/*physiopathology
Aged ; Biomarkers/blood ; Blood Glucose/metabolism ; Clinical Decision-Making ; Cross-Sectional Studies ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/diagnosis ; Electric Impedance ; Female ; Humans ; Hypoglycemic Agents/adverse effects ; Infusions, Subcutaneous ; Insulin/adverse effects ; Male ; Middle Aged ; Obesity/complications ; Obesity/diagnosis ; Predictive Value of Tests ; Time Factors ; Treatment Outcome
-
References:
-
Diabetes Care. 2019 Mar;42(3):400-405. (PMID: 30352896)
Biochim Biophys Acta. 2010 Mar;1801(3):209-14. (PMID: 19948243)
Diabetes Technol Ther. 2019 Feb;21(2):81-85. (PMID: 30575414)
Ann Nutr Metab. 2016;68(4):235-43. (PMID: 27161795)
Diabet Med. 2005 Aug;22(8):1037-46. (PMID: 16026370)
Obes Res Clin Pract. 2014 Jul-Aug;8(4):e350-5. (PMID: 25091356)
Eur Heart J. 2013 Feb;34(5):389-97. (PMID: 22947612)
Diabetes Care. 2004 May;27(5):1028-32. (PMID: 15111515)
Diabetes Technol Ther. 2020 Jul;22(7):492-500. (PMID: 31886733)
Lancet Diabetes Endocrinol. 2013 Sep;1(1):28-34. (PMID: 24622264)
J Nutr. 2019 Jul 1;149(7):1288-1293. (PMID: 31132115)
Nutrition. 2001 Jan;17(1):26-30. (PMID: 11165884)
BMC Public Health. 2020 Apr 6;20(1):452. (PMID: 32252701)
Diabetes Care. 2012 Mar;35(3):474-81. (PMID: 22228747)
Diabetes Res Clin Pract. 2016 Dec;122:62-70. (PMID: 27810687)
Int J Clin Pract. 2014 Jun;68(6):682-91. (PMID: 24548654)
Diabetes Res Clin Pract. 2016 Oct;120:65-72. (PMID: 27522035)
Diabetes Technol Ther. 2018 Jun;20(S2):S25-S215. (PMID: 29916742)
Diabetes Res Clin Pract. 2018 May;139:122-130. (PMID: 29448005)
Diabetes Metab Syndr Obes. 2018 Dec 21;12:75-83. (PMID: 30613158)
J Diabetes Res. 2020 Aug 5;2020:1581726. (PMID: 32832557)
Front Endocrinol (Lausanne). 2018 May 14;9:238. (PMID: 29867770)
Diabetes Obes Metab. 2018 Mar;20(3):681-688. (PMID: 29095564)
Diabetes. 2013 May;62(5):1398-404. (PMID: 23613565)
Lancet. 2008 May 24;371(9626):1753-60. (PMID: 18502299)
Diabetes Res Clin Pract. 2020 Aug;166:108289. (PMID: 32615278)
Diabetes Care. 2004 Nov;27(11):2597-602. (PMID: 15504992)
Int J Obes (Lond). 2010 Dec;34 Suppl 2:S4-17. (PMID: 21151146)
Nat Rev Endocrinol. 2019 May;15(5):288-298. (PMID: 30814686)
Diabetes Care. 2018 Nov;41(11):2370-2376. (PMID: 30201847)
Diabet Med. 1998 Jul;15(7):539-53. (PMID: 9686693)
Diabetes Care. 2020 Jan;43(Suppl 1):S77-S88. (PMID: 31862750)
Endocrine. 2018 May;60(2):292-300. (PMID: 29411305)
Food Chem Toxicol. 2017 Feb;100:161-167. (PMID: 28027979)
Diabetes Metab Syndr. 2019 Mar - Apr;13(2):1241-1244. (PMID: 31336471)
Clin Cardiol. 2019 Jan;42(1):129-135. (PMID: 30447075)
J Diabetes Res. 2020 Feb 6;2020:5817074. (PMID: 32090120)
Intern Med. 2014;53(5):383-90. (PMID: 24583424)
Diabetes Care. 2019 Aug;42(8):1593-1603. (PMID: 31177185)
Diabetes Technol Ther. 2020 Feb;22(2):72-78. (PMID: 31524497)
-
Substance Nomenclature:
-
0 (Biomarkers)
0 (Blood Glucose)
0 (Hypoglycemic Agents)
0 (Insulin)
-
Entry Date(s):
-
Date Created: 20210617 Date Completed: 20211210 Latest Revision: 20220424
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC8177984
-
DOI:
-
10.1155/2021/5551216
-
PMID:
-
34136580
-
Background: Obesity is a crucial risk factor associated with type 2 diabetes mellitus (T2DM). Excessive accumulation of body fat may affect the glycemia control in T2DM. This study investigated the relationship between body fat percentage and time in range (TIR) assessed by continuous glucose monitoring (CGM) during short-term continuous subcutaneous insulin infusion (CSII) therapy in T2DM patients.
Method: A total of 85 T2DM patients were recruited in this cross-sectional study. All participants underwent 72 h CGM period during short-term CSII therapy. TIR was defined as the percentage of time spent within the target glucose range of 3.9-10.0 mmol/L. Body composition was measured using bioelectrical impedance analysis (BIA) and overfat was defined as an amount of body fat of at least 25% of total body mass for men or at least 30% for women. Multiple linear regression models were used to evaluate the independent association of body fat percentage with TIR after adjusting for confounding factors.
Results: Compared with normal fat T2DM patients, individual with a higher body fat percentage exhibited lower levels of TIR ( P = 0.004) and higher 72 h mean blood glucose (72 h MBG) ( P = 0.001) during short-term CSII treatment. The prevalence of overfat assessed by body fat percentage decreased with the ascending TIR tertiles ( P < 0.05). Multiple linear regression analysis indicated that body fat percentage was significantly associated with TIR independent of age, gender, diabetes duration, HbA1c, and BMI ( P = 0.043).
Conclusions: Body fat percentage was significantly associated with TIR in T2DM during short-term CSII therapy. Reduction of body fat may be an important therapeutic target to improve glycemic control in high body fat T2DM patients, who may benefit less from intensive insulin treatment.
Competing Interests: The authors declared that they have no competing interests.
(Copyright © 2021 Yuting Ruan et al.)